Share Price and Basic Stock Data
Last Updated: November 4, 2025, 12:14 am
| PEG Ratio | 42.46 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Hindustan Bio Sciences Ltd operates within the Trading & Distributors industry and has reported a current share price of ₹6.50, with a market capitalization of ₹6.66 Cr. The company has experienced fluctuating revenue streams, with total sales for the fiscal year ending March 2023 recorded at ₹0.92 Cr, a decline from ₹1.03 Cr in March 2022. Quarterly sales data shows notable variability; for instance, sales of ₹0.33 Cr were reported in March 2023, followed by a dip to ₹0.00 Cr in June 2023. However, sales rebounded to ₹0.32 Cr in September 2023 and remained stable through December 2023. This inconsistency suggests potential seasonal influences or operational challenges affecting sales performance. The trailing twelve months (TTM) revenue stood at ₹0.70 Cr, reflecting ongoing struggles to stabilize income in a competitive market. Overall, the company’s revenue trends indicate a need for strategic adjustments to enhance sales consistency and growth.
Profitability and Efficiency Metrics
Hindustan Bio Sciences Ltd reported a net profit of ₹0.03 Cr for the year ended March 2025, indicating a slight improvement from a net loss of ₹0.04 Cr in March 2023. The profit before tax for the same period rose to ₹0.10 Cr, highlighting a gradual recovery in profitability. However, the company’s operating profit margin (OPM) remains low, recorded at 12.35% for March 2025, compared to negative margins in prior years. The return on equity (ROE) stood at 11.8%, suggesting that the company is generating a reasonable return on shareholders’ investment, while the return on capital employed (ROCE) was reported at 2.95%, indicating challenges in effectively utilizing capital for generating profits. The cash conversion cycle (CCC) of 198.27 days is concerning, as it signifies prolonged periods in converting investments into cash, potentially straining liquidity and operational efficiency. Overall, while there are signs of profitability, the company must address efficiency and margin issues to sustain growth.
Balance Sheet Strength and Financial Ratios
As of March 2025, Hindustan Bio Sciences Ltd’s balance sheet reveals total borrowings of ₹2.51 Cr against reserves of -₹1.15 Cr, indicating a leveraged position with negative equity. The debt-to-equity ratio stood at 2.77x, suggesting significant reliance on debt financing, which may pose risks in adverse market conditions. The current ratio at 73.31x indicates an exceptionally strong liquidity position, although this figure appears unusually high and may reflect an overabundance of current assets relative to current liabilities, which could be inefficient. The interest coverage ratio (ICR) of 71.29x illustrates the company’s ability to meet interest obligations comfortably, yet the sustainability of such high leverage warrants scrutiny. Financial ratios suggest a company in transition, with a need to balance growth initiatives with prudent financial management to improve overall stability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Hindustan Bio Sciences Ltd reveals that promoters hold 12.19% of the equity, while the public owns a substantial 87.81%. The total number of shareholders has increased from 8,879 in December 2022 to 11,405 by March 2025, indicating growing interest and potentially enhanced investor confidence. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may reflect a lack of institutional backing, which could be a concern for long-term stability. The public holding’s dominance suggests the company may need to engage more actively with institutional investors to bolster credibility and share liquidity. Overall, while the increasing number of shareholders is a positive sign, the lack of institutional investment could constrain the company’s growth potential and market perception.
Outlook, Risks, and Final Insight
Hindustan Bio Sciences Ltd faces a mixed outlook amid improving profitability metrics and increasing shareholder base. Key strengths include the reported return on equity of 11.8% and a high interest coverage ratio of 71.29x, suggesting financial resilience. However, significant risks persist, notably the negative reserves and high debt levels, which could impair financial flexibility. The erratic revenue patterns and prolonged cash conversion cycle also present challenges that must be addressed. The company’s ability to maintain profitability and manage its debt will be critical in the coming periods. If Hindustan Bio Sciences can stabilize its revenue and improve operational efficiency, it may enhance investor confidence and attract institutional interest. Conversely, failure to address financial risks and operational inefficiencies could hinder growth prospects and shareholder returns in a competitive landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Hindustan Bio Sciences Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| MKP Mobility Ltd | 40.7 Cr. | 119 | 264/103 | 48.5 | 19.3 | 0.00 % | 19.6 % | 4.35 % | 10.0 |
| Mrugesh Trading Ltd | 0.51 Cr. | 2.10 | 2.10/0.48 | 1.47 | 73.5 | 0.00 % | 4.43 % | 3.81 % | 1.00 |
| Mukta Agriculture Ltd | 6.50 Cr. | 3.00 | 7.84/2.54 | 10.3 | 0.00 % | 0.57 % | 0.63 % | 10.0 | |
| Hindustan Bio Sciences Ltd | 7.66 Cr. | 7.47 | 11.8/6.50 | 383 | 0.84 | 0.00 % | 2.95 % | 11.8 % | 2.00 |
| Hindustan Appliances Ltd | 176 Cr. | 176 | 402/85.0 | 1,467 | 14.6 | 0.00 % | 0.30 % | 1.03 % | 10.0 |
| Industry Average | 292.00 Cr | 101.26 | 388.43 | 33.92 | 0.00% | 6.43% | 5.06% | 7.17 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.27 | 0.00 | 0.32 | 0.33 | 0.00 | 0.32 | 0.32 | 0.39 | 0.41 | 0.00 | 0.00 | 0.38 | 0.32 |
| Expenses | 0.29 | 0.07 | 0.27 | 0.31 | 0.12 | 0.26 | 0.26 | 0.35 | 0.34 | 0.05 | 0.04 | 0.28 | 0.32 |
| Operating Profit | -0.02 | -0.07 | 0.05 | 0.02 | -0.12 | 0.06 | 0.06 | 0.04 | 0.07 | -0.05 | -0.04 | 0.10 | 0.00 |
| OPM % | -7.41% | 15.62% | 6.06% | 18.75% | 18.75% | 10.26% | 17.07% | 26.32% | 0.00% | ||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.02 | -0.07 | 0.05 | 0.02 | -0.12 | 0.07 | 0.07 | 0.04 | 0.08 | -0.05 | -0.04 | 0.11 | 0.01 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.03 | -0.07 | 0.05 | 0.01 | -0.12 | 0.07 | 0.07 | 0.04 | 0.08 | -0.05 | -0.04 | 0.11 | 0.01 |
| EPS in Rs | -0.03 | -0.07 | 0.05 | 0.01 | -0.12 | 0.07 | 0.07 | 0.04 | 0.08 | -0.05 | -0.04 | 0.11 | 0.01 |
Last Updated: August 19, 2025, 1:50 pm
Below is a detailed analysis of the quarterly data for Hindustan Bio Sciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.32 Cr.. The value appears to be declining and may need further review. It has decreased from 0.38 Cr. (Mar 2025) to 0.32 Cr., marking a decrease of 0.06 Cr..
- For Expenses, as of Jun 2025, the value is 0.32 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.28 Cr. (Mar 2025) to 0.32 Cr., marking an increase of 0.04 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.10 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.10 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value appears to be declining and may need further review. It has decreased from 26.32% (Mar 2025) to 0.00%, marking a decrease of 26.32%.
- For Other Income, as of Jun 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.11 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.10 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.11 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.10 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.01. The value appears to be declining and may need further review. It has decreased from 0.11 (Mar 2025) to 0.01, marking a decrease of 0.10.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 12:57 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.25 | 0.75 | 1.26 | 1.01 | 1.03 | 3.56 | 1.94 | 1.03 | 0.43 | 0.92 | 1.05 | 0.81 | 0.70 |
| Expenses | 2.96 | 1.97 | 1.38 | 1.48 | 3.38 | 3.43 | 1.80 | 1.97 | 0.94 | 0.95 | 0.99 | 0.71 | 0.69 |
| Operating Profit | -0.71 | -1.22 | -0.12 | -0.47 | -2.35 | 0.13 | 0.14 | -0.94 | -0.51 | -0.03 | 0.06 | 0.10 | 0.01 |
| OPM % | -31.56% | -162.67% | -9.52% | -46.53% | -228.16% | 3.65% | 7.22% | -91.26% | -118.60% | -3.26% | 5.71% | 12.35% | 1.43% |
| Other Income | -0.04 | -0.01 | -1.92 | 0.00 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Interest | 0.03 | 0.03 | 0.03 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.22 | 0.18 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
| Profit before tax | -1.00 | -1.44 | -2.08 | -0.49 | -2.27 | 0.11 | 0.12 | -0.96 | -0.51 | -0.04 | 0.05 | 0.10 | 0.03 |
| Tax % | 0.00% | 0.69% | 0.00% | 0.00% | 0.00% | 0.00% | 33.33% | -2.08% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Net Profit | -0.99 | -1.46 | -2.09 | -0.49 | -2.28 | 0.11 | 0.08 | -0.94 | -0.52 | -0.04 | 0.06 | 0.10 | 0.03 |
| EPS in Rs | -0.97 | -1.42 | -2.04 | -0.48 | -2.22 | 0.11 | 0.08 | -0.92 | -0.51 | -0.04 | 0.06 | 0.10 | 0.03 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -47.47% | -43.15% | 76.56% | -365.31% | 104.82% | -27.27% | -1275.00% | 44.68% | 92.31% | 250.00% | 66.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 4.32% | 119.71% | -441.86% | 470.13% | -132.10% | -1247.73% | 1319.68% | 47.63% | 157.69% | -183.33% |
Hindustan Bio Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: July 25, 2025, 1:06 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 2.05 | 2.05 | 2.05 |
| Reserves | -1.83 | -3.34 | -5.43 | -5.92 | -8.20 | -8.09 | -8.01 | -8.95 | -9.46 | -1.30 | -1.25 | -1.15 |
| Borrowings | 0.77 | 0.97 | 0.94 | 1.30 | 1.57 | 3.37 | 2.60 | 1.86 | 2.17 | 2.46 | 2.56 | 2.51 |
| Other Liabilities | 0.48 | 0.17 | 0.12 | 0.24 | 0.09 | 0.10 | 0.71 | 0.32 | 0.02 | 0.08 | 0.01 | 0.01 |
| Total Liabilities | 9.67 | 8.05 | 5.88 | 5.87 | 3.71 | 5.63 | 5.55 | 3.48 | 2.98 | 3.29 | 3.37 | 3.42 |
| Fixed Assets | 0.16 | 0.08 | 0.07 | 0.06 | 0.06 | 0.06 | 0.05 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 |
| CWIP | 1.92 | 1.92 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 7.59 | 6.05 | 5.81 | 5.81 | 3.65 | 5.57 | 5.50 | 3.44 | 2.94 | 3.26 | 3.34 | 3.39 |
| Total Assets | 9.67 | 8.05 | 5.88 | 5.87 | 3.71 | 5.63 | 5.55 | 3.48 | 2.98 | 3.29 | 3.37 | 3.42 |
Below is a detailed analysis of the balance sheet data for Hindustan Bio Sciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 2.05 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 2.05 Cr..
- For Reserves, as of Mar 2025, the value is -1.15 Cr.. The value appears to be improving (becoming less negative). It has improved from -1.25 Cr. (Mar 2024) to -1.15 Cr., marking an improvement of 0.10 Cr..
- For Borrowings, as of Mar 2025, the value is 2.51 Cr.. The value appears to be improving (decreasing). However, Reserves are negative, which is a major warning sign. It has decreased from 2.56 Cr. (Mar 2024) to 2.51 Cr., marking a decrease of 0.05 Cr..
- For Other Liabilities, as of Mar 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.01 Cr..
- For Total Liabilities, as of Mar 2025, the value is 3.42 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.37 Cr. (Mar 2024) to 3.42 Cr., marking an increase of 0.05 Cr..
- For Fixed Assets, as of Mar 2025, the value is 0.03 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.03 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 3.39 Cr.. The value appears strong and on an upward trend. It has increased from 3.34 Cr. (Mar 2024) to 3.39 Cr., marking an increase of 0.05 Cr..
- For Total Assets, as of Mar 2025, the value is 3.42 Cr.. The value appears strong and on an upward trend. It has increased from 3.37 Cr. (Mar 2024) to 3.42 Cr., marking an increase of 0.05 Cr..
However, the Borrowings (2.51 Cr.) are higher than the Reserves (-1.15 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.48 | -2.19 | -1.06 | -1.77 | -3.92 | -3.24 | -2.46 | -2.80 | -2.68 | -2.49 | -2.50 | -2.41 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 202.78 | 155.73 | 136.15 | 169.85 | 113.40 | 171.22 | 255.88 | 219.71 | 118.84 | 178.53 | 152.95 | 198.27 |
| Inventory Days | 36.08 | 25.08 | 0.00 | 0.00 | 51.23 | 13.89 | 95.46 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days Payable | 84.88 | 39.01 | 44.82 | 7.58 | 185.31 | |||||||
| Cash Conversion Cycle | 153.97 | 141.80 | 136.15 | 169.85 | 119.80 | 177.54 | 166.03 | 219.71 | 118.84 | 178.53 | 152.95 | 198.27 |
| Working Capital Days | 186.56 | 111.93 | -63.73 | -191.53 | -170.10 | 85.10 | 86.55 | -148.83 | -500.81 | -226.14 | 312.86 | 441.60 |
| ROCE % | -9.91% | -16.40% | -1.91% | -8.43% | -49.08% | 2.62% | 2.51% | -23.75% | -16.67% | -1.30% | 1.52% | 2.95% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.10 | 0.06 | -0.04 | -0.50 | -0.92 |
| Diluted EPS (Rs.) | 0.10 | 0.06 | -0.04 | -0.50 | -0.92 |
| Cash EPS (Rs.) | 0.09 | 0.06 | -0.03 | -0.50 | -0.90 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 0.88 | 0.78 | 0.72 | 0.76 | 1.27 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 0.88 | 0.78 | 0.72 | 0.76 | 1.27 |
| Revenue From Operations / Share (Rs.) | 0.79 | 1.03 | 0.89 | 0.42 | 1.01 |
| PBDIT / Share (Rs.) | 0.09 | 0.06 | -0.02 | -0.49 | -0.91 |
| PBIT / Share (Rs.) | 0.09 | 0.05 | -0.03 | -0.49 | -0.92 |
| PBT / Share (Rs.) | 0.09 | 0.05 | -0.03 | -0.50 | -0.93 |
| Net Profit / Share (Rs.) | 0.09 | 0.05 | -0.03 | -0.50 | -0.91 |
| PBDIT Margin (%) | 12.27 | 6.06 | -3.05 | -117.53 | -91.13 |
| PBIT Margin (%) | 12.24 | 5.41 | -3.67 | -118.32 | -91.91 |
| PBT Margin (%) | 12.07 | 5.06 | -4.11 | -119.47 | -92.57 |
| Net Profit Margin (%) | 12.39 | 5.47 | -4.38 | -120.18 | -91.07 |
| Return on Networth / Equity (%) | 11.13 | 7.16 | -5.41 | -65.75 | -72.04 |
| Return on Capital Employeed (%) | 2.92 | 1.69 | -1.81 | -27.41 | -46.54 |
| Return On Assets (%) | 2.94 | 1.70 | -1.23 | -17.39 | -26.95 |
| Long Term Debt / Equity (X) | 2.77 | 3.18 | 1.50 | 1.36 | 0.56 |
| Total Debt / Equity (X) | 2.77 | 3.18 | 3.29 | 2.75 | 1.42 |
| Asset Turnover Ratio (%) | 0.23 | 0.31 | 0.29 | 0.13 | 0.22 |
| Current Ratio (X) | 73.31 | 69.04 | 0.60 | 0.48 | 0.72 |
| Quick Ratio (X) | 73.31 | 69.04 | 0.60 | 0.48 | 0.72 |
| Interest Coverage Ratio (X) | 71.29 | 17.33 | -6.88 | -101.64 | -136.86 |
| Interest Coverage Ratio (Post Tax) (X) | 73.00 | 16.63 | -8.87 | -102.94 | -135.78 |
| Enterprise Value (Cr.) | 9.65 | 9.95 | 7.81 | 6.48 | 4.92 |
| EV / Net Operating Revenue (X) | 11.86 | 9.45 | 8.47 | 15.06 | 4.77 |
| EV / EBITDA (X) | 96.69 | 155.82 | -277.11 | -12.81 | -5.23 |
| MarketCap / Net Operating Revenue (X) | 8.80 | 7.06 | 5.91 | 10.05 | 2.98 |
| Price / BV (X) | 7.91 | 9.24 | 7.31 | 5.50 | 2.36 |
| Price / Net Operating Revenue (X) | 8.80 | 7.06 | 5.91 | 10.05 | 2.98 |
| EarningsYield | 0.01 | 0.01 | -0.01 | -0.11 | -0.30 |
After reviewing the key financial ratios for Hindustan Bio Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 5. It has increased from 0.06 (Mar 24) to 0.10, marking an increase of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 5. It has increased from 0.06 (Mar 24) to 0.10, marking an increase of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 3. It has increased from 0.06 (Mar 24) to 0.09, marking an increase of 0.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.88. It has increased from 0.78 (Mar 24) to 0.88, marking an increase of 0.10.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.88. It has increased from 0.78 (Mar 24) to 0.88, marking an increase of 0.10.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.79. It has decreased from 1.03 (Mar 24) to 0.79, marking a decrease of 0.24.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 2. It has increased from 0.06 (Mar 24) to 0.09, marking an increase of 0.03.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from 0.05 (Mar 24) to 0.09, marking an increase of 0.04.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from 0.05 (Mar 24) to 0.09, marking an increase of 0.04.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 2. It has increased from 0.05 (Mar 24) to 0.09, marking an increase of 0.04.
- For PBDIT Margin (%), as of Mar 25, the value is 12.27. This value is within the healthy range. It has increased from 6.06 (Mar 24) to 12.27, marking an increase of 6.21.
- For PBIT Margin (%), as of Mar 25, the value is 12.24. This value is within the healthy range. It has increased from 5.41 (Mar 24) to 12.24, marking an increase of 6.83.
- For PBT Margin (%), as of Mar 25, the value is 12.07. This value is within the healthy range. It has increased from 5.06 (Mar 24) to 12.07, marking an increase of 7.01.
- For Net Profit Margin (%), as of Mar 25, the value is 12.39. This value exceeds the healthy maximum of 10. It has increased from 5.47 (Mar 24) to 12.39, marking an increase of 6.92.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.13. This value is below the healthy minimum of 15. It has increased from 7.16 (Mar 24) to 11.13, marking an increase of 3.97.
- For Return on Capital Employeed (%), as of Mar 25, the value is 2.92. This value is below the healthy minimum of 10. It has increased from 1.69 (Mar 24) to 2.92, marking an increase of 1.23.
- For Return On Assets (%), as of Mar 25, the value is 2.94. This value is below the healthy minimum of 5. It has increased from 1.70 (Mar 24) to 2.94, marking an increase of 1.24.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 2.77. This value exceeds the healthy maximum of 1. It has decreased from 3.18 (Mar 24) to 2.77, marking a decrease of 0.41.
- For Total Debt / Equity (X), as of Mar 25, the value is 2.77. This value exceeds the healthy maximum of 1. It has decreased from 3.18 (Mar 24) to 2.77, marking a decrease of 0.41.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.23. It has decreased from 0.31 (Mar 24) to 0.23, marking a decrease of 0.08.
- For Current Ratio (X), as of Mar 25, the value is 73.31. This value exceeds the healthy maximum of 3. It has increased from 69.04 (Mar 24) to 73.31, marking an increase of 4.27.
- For Quick Ratio (X), as of Mar 25, the value is 73.31. This value exceeds the healthy maximum of 2. It has increased from 69.04 (Mar 24) to 73.31, marking an increase of 4.27.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 71.29. This value is within the healthy range. It has increased from 17.33 (Mar 24) to 71.29, marking an increase of 53.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 73.00. This value is within the healthy range. It has increased from 16.63 (Mar 24) to 73.00, marking an increase of 56.37.
- For Enterprise Value (Cr.), as of Mar 25, the value is 9.65. It has decreased from 9.95 (Mar 24) to 9.65, marking a decrease of 0.30.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 11.86. This value exceeds the healthy maximum of 3. It has increased from 9.45 (Mar 24) to 11.86, marking an increase of 2.41.
- For EV / EBITDA (X), as of Mar 25, the value is 96.69. This value exceeds the healthy maximum of 15. It has decreased from 155.82 (Mar 24) to 96.69, marking a decrease of 59.13.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.80. This value exceeds the healthy maximum of 3. It has increased from 7.06 (Mar 24) to 8.80, marking an increase of 1.74.
- For Price / BV (X), as of Mar 25, the value is 7.91. This value exceeds the healthy maximum of 3. It has decreased from 9.24 (Mar 24) to 7.91, marking a decrease of 1.33.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.80. This value exceeds the healthy maximum of 3. It has increased from 7.06 (Mar 24) to 8.80, marking an increase of 1.74.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hindustan Bio Sciences Ltd:
- Net Profit Margin: 12.39%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 2.92% (Industry Average ROCE: 6.43%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.13% (Industry Average ROE: 5.06%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 73
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 73.31
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 383 (Industry average Stock P/E: 388.43)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 2.77
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.39%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Trading & Distributors | H.No.8-2-269/S, Plot No.31, Sagar Co-Operative Housing Society, Hyderabad Telangana 500034 | pharma.hindustanbio@gmail.com www.hindustanbiosciences.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. J V R Mohan Raju | Chairman & Managing Director |
| Mrs. J Uma | Director |
| Mr. Jaison George | Director |
| Mr. Reji Abraham | Independent Director |
| Mr. B Nagi Reddy | Independent Director |
| Mr. G Prateek Reddy | Independent Director |
FAQ
What is the intrinsic value of Hindustan Bio Sciences Ltd?
Hindustan Bio Sciences Ltd's intrinsic value (as of 03 November 2025) is 30.98 which is 314.73% higher the current market price of 7.47, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 7.66 Cr. market cap, FY2025-2026 high/low of 11.8/6.50, reserves of ₹-1.15 Cr, and liabilities of 3.42 Cr.
What is the Market Cap of Hindustan Bio Sciences Ltd?
The Market Cap of Hindustan Bio Sciences Ltd is 7.66 Cr..
What is the current Stock Price of Hindustan Bio Sciences Ltd as on 03 November 2025?
The current stock price of Hindustan Bio Sciences Ltd as on 03 November 2025 is 7.47.
What is the High / Low of Hindustan Bio Sciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Hindustan Bio Sciences Ltd stocks is 11.8/6.50.
What is the Stock P/E of Hindustan Bio Sciences Ltd?
The Stock P/E of Hindustan Bio Sciences Ltd is 383.
What is the Book Value of Hindustan Bio Sciences Ltd?
The Book Value of Hindustan Bio Sciences Ltd is 0.84.
What is the Dividend Yield of Hindustan Bio Sciences Ltd?
The Dividend Yield of Hindustan Bio Sciences Ltd is 0.00 %.
What is the ROCE of Hindustan Bio Sciences Ltd?
The ROCE of Hindustan Bio Sciences Ltd is 2.95 %.
What is the ROE of Hindustan Bio Sciences Ltd?
The ROE of Hindustan Bio Sciences Ltd is 11.8 %.
What is the Face Value of Hindustan Bio Sciences Ltd?
The Face Value of Hindustan Bio Sciences Ltd is 2.00.